Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
BioDrugs · 2024-09 · 38 (5) · 691-702
DOI: 10.1007/s40259-024-00673-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioDrugs, online erschienen am 22.08.2024. Verfasst von Ashish Srinivasan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia. ashish.srinivasan1@gmail.com. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Melbourne.
Abstract (Originalsprache)
BACKGROUND: The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic infliximab trough levels remains uncertain, as does whether post-intensification trough and treatment targets should influence this decision. OBJECTIVES: This pharmacokinetic simulation study aimed to identify infliximab dose intensification strategies capable of achieving post-intensification infliximab trough thresholds associated with clinical and objective treatment targets in Crohn's disease and ulcerative colitis. METHODS: A validated pharmacokinetic infliximab model, applied to 200 simulated patients, identified those with subtherapeutic ( 7.50 mg/L, Crohn's disease > 9.70 mg/L) was the primary outcome, with perianal fistula healing (Crohn's disease > 10.10 mg/L) and clinical improvement (ulcerative colitis > 3.70 mg/L, Crohn's disease > 7.00mg/L) evaluated as secondary outcomes. All outcomes were stratified by intensity of dose intensification, with standard (≤ 10 mg/kg 8-weekly or 5 mg/kg 4-weekly; n = 5) and intensive (> 10 mg/kg 8-weekly or 5 mg/kg 4-weekly; n = 5) dosing strategies defined, respectively. RESULTS: The median pre-intensification infliximab trough level was 0.91 mg/L (interquartile range 1.37). Intensive dosing strategies were more likely to achieve infliximab trough concentrations associated with endoscopic remission (ulcerative colitis 36.48% vs. 10.80%, Crohn's disease 25.98 vs. 4.68%), perianal fistula healing (24.52% vs. 4.36%) and clinical improvement (ulcerative colitis 61.90% vs. 34.86%, Crohn's disease 40.32 vs. 12.08%) than standard intensification strategies (all p < 0.01). When controlling for cumulative (mg/kg) infliximab dose over 32 weeks, strategies that concurrently dose increased and interval shortened achieved the highest infliximab trough levels (all p < 0.01). CONCLUSION: This simulation-based analysis highlights the potential of using post-intensification infliximab trough thresholds associated with aspirational treatment targets in Crohn's disease and ulcerative colitis to guide choice of infliximab dose intensification strategy. Intensive dose intensification strategies, particularly those that concurrently dose increase and interval shorten, appear to achieve higher infliximab levels than standard dose intensification strategies. This may be particularly important in the pursuit of stringent endpoints, such as endoscopic remission and fistula healing, which have been consistently associated with higher infliximab trough levels. These findings require validation across real-world cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia. ashish.srinivasan1@gmail.com.
- Monash University, Eastern Health Clinical School, Melbourne, VIC, Australia. ashish.srinivasan1@gmail.com.
- Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia. ashish.srinivasan1@gmail.com.
- The University of Melbourne, Austin Academic Centre, Melbourne, VIC, Australia. ashish.srinivasan1@gmail.com.
- Monash University, Eastern Health Clinical School, Melbourne, VIC, Australia.
- Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
Förderung
- University of Melbourne
Zitieren
APA
Srinivasan, A., van Langenberg, D., De Cruz, P., Segal, J., Vasudevan, A., & Upton, R. N. (2024). Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs, 38(5), 691-702. https://doi.org/10.1007/s40259-024-00673-2
Vancouver
Srinivasan A, van Langenberg D, De Cruz P, Segal J, Vasudevan A, Upton RN. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs. 2024;38(5):691-702. doi:10.1007/s40259-024-00673-2
BibTeX
@article{Srinivasan2024,
author = {Srinivasan, Ashish and van Langenberg, Daniel and De Cruz, Peter and Segal, Jonathan and Vasudevan, Abhinav and Upton, Richard N},
title = {Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study},
journal = {BioDrugs},
year = {2024},
volume = {38},
number = {5},
pages = {691--702},
doi = {10.1007/s40259-024-00673-2}
}
EUVIMED